AbbVie's ABBV-295 Shows Up to 9.8% Weight Loss in Phase 1, Supports Monthly Dosing
ABBV sits 40% above its 52-week low of $190.75.
Summary
AbbVie presented detailed Phase 1 data for ABBV-295, a long-acting amylin analog, at EASD 2026. The drug showed dose-dependent weight loss of 7.8% to 9.8% at 12 weeks across weekly, every-other-week, and monthly regimens, with a half-life of 10.7-12.3 days supporting less frequent dosing. GI side effects were mostly mild, with no serious adverse events. A Phase 2 trial in obesity was initiated in August 2026. This is a differentiated mechanism from GLP-1s, and the data support advancement into later-stage trials. The news is positive for AbbVie's obesity pipeline, though the program is still early-stage.
At the time of this announcement, ABBV was trading at $266.97 on NYSE in the Life Sciences sector, with a market capitalization of approximately $465.3B. The 52-week trading range was $190.75 to $269.39. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: MFN by Modular Finance.